Skip to main content

Advertisement

Table 13 Assay results for the determination of VPS and SFV in their co-formulated tablet by Method 2

From: Two novel UPLC methods utilizing two different analytical columns and different detection approaches for the simultaneous analysis of velpatasvir and sofosbuvir: application to their co-formulated tablet

Studied drug Proposed method Comparison method [11]
Amount taken (ng/mL) Amount found (ng/mL) % Found % Found
Column (A) Column (B) Column (A) Column (B) Column (A) Column (B)
SFV Epclusa® tablet (SFV 400 mg/VPS 100 mg) 200.0 200.0 196.900 199.520 98.45 99.76 99.98
400.0 400.0 389.760 394.920 97.44 98.73 98.93
600.0 600.0 596.760 589.080 99.46 98.18 100.83
Mean      98.45 98.89 100.85
 ±SD      1.01 0.80 0.95
t-test      1.83 1.42 (2.78)*
F-test      1.12 1.41 (19)*
VPS 50.0 50.0 48.810 49.955 97.62 99.91 102.45
Epclusa® tablet (SFV 400 mg/VPS 100 mg) 100.0 100.0 98.000 98.040 98.00 98.04 101.78
150.0 150.0 148.665 148.185 99.11 98.79 98.91
Mean      98.24 98.91 101.05
 ±SD      0.77 0.94 1.88
t-test      2.39 1.76 (2.78)*
F-test      5.89 3.99 (19.0)*
  1. Each result is the average of three separate determinations
  2. * The figures between parentheses are the tabulated t and F values at P = 0.05 [17]